1. Hoffman JI, Kaplan S. The incidence of congenital heart disease.J Am Coll Cardiol. 2002; 39: 1890-900.
2. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107: 1-8.
3. Geva T, Martins JD, Wald RM. Atrial septal defects. Lancet. 2014;383:1921-32.
4. Darmoch F, Al-Khadra Y, Bacha HM, Soud M, Alraies MC. Closing the gap on patent foramen ovale and cryptogenic stroke. Expert Rev Cardiovasc Ther. 2019; 11:1-6.
5. Lempereur M, Lancellotti P. Percutaneous treatment of atrial septal defect and patent foramen ovale. Rev Med Liege. 2019;74(S1):S87-96.
6. Yoshimura A, Iriki Y, Ichiki H, Oketani N, Okui H, Maenosono R, Namino F, Miyata M, Ohishi M. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. J Cardiol. 2017; 69 (1): 228-35.
7. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, et al. PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AFTrials. J Am Coll Cardiol. 2017.19;70(24):2964-75.
8. Bergmann MW, Ince H, Kische S, Schmitz T, Meincke F, Schmidt B, Foley D, Betts TR, Grygier M, Protopopov AV, Stein KM,et al. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention. 2018; 13 (17):2003-11.
9. MasoudiFA.The evolution of left atrial appendage occlusion:EWOLUTION and the WATCHMAN in practice. Eur Heart J. 2016; 37(31):2475-7.
10. Komar M, Prewlocki T, Olszowska M, Sobień B, Stępniewski J, Podolec J, Mleczko S, Tomkiewicz-Pająk L, Zmudka K, Podolec P. Conduction abnormality and arrhythmia after transcatheter closure of atrial septal defect.Circ J.2014;78(10):2415-21.
11. Wi J, Choi JY, Shim JM, Uhm JS, Hwang HJ, Kim JY, Pak HN, Joung B, Lee M. Fate of preoperative atrial fibrillation after correction of atrial septal defect. CircJ.2013;77(1):109-15.
12. Attie F, Rosas M, Granados N, Zabal C, Buendía A, Calderón J. Surgical treatment for secundum atrial septal defects in patients >40 years old. A randomized clinical trial. J Am Coll Cardiol. 2001;38(7):2035-42.
13. Chen L, Bai Y, Wang FY, Zhang ZG, Shan XH, Chen T, Zhao XX, Qin YW. Transcatheter closure of atrial septal defects improves cardiac remodeling and function of adult patients with permanent atrial fibrillation.Chin Med J (Engl). 2015;128(6):780-3.
14. Webb G, Gatzoulis MA. Atrial septal defects in the adult:recent progress and overview. Circulation.2006;114:1645 - 53.
15. Li H, Qingyao, Bingshen, Shu M, Lizhong, Wang X, Song Z. Application of 3D printing technology to left atrial appendage occlusion. Int J Cardiol. 2017;231:258-63.
16. Song ZY, Shu MQ, Hu HY, Tong SF, Ran BL, Liu JP, Li YH, He GX. Clinical efficiency and safety analysis of transcatheter interventional therapy for compound congenital cardiovascular abnormalities. Clin Cardiol. 2007; 30(10):518-21.
17. Attie F, Rosas M, Granados N, Zabal C, Buendía A, Calderón J. Surgical treatment for secundum atrial septal defects in patients >40 years old. A randomized clinical trial. Journal of the American College of Cardiology. 2001;38:2035-42.
18. Mandalenakis Z, Rosengren A, Lappas G, Eriksson P, Gilljam T, Hansson PO, Skoglund K, Fedchenko M, Dellborg M.Atrial Fibrillation Burden in Young Patients with Congenital Heart Disease. Circulation. 2018;137(9):928-37.
19. Miyasaka Y, Barnes M, Gersh B, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation.2006;114:119-25.
20. Nyboe C, Olsen MS, Nielsen-Kudsk JE, Hjortdal VE.Atrial fibrillation and stroke in adult patients with atrial septal defect and the long-term effect of closure. Heart.2015;101(9):706- 11.
21. Anthony J, Mark Reisman, Joseph Massaro, Laura Mauri, Harold Adams, Gregory W, Robert Felberg, Howard Herrmann, Saibal Kar, Michael Landzberg, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med.2012;366: 991-9.
22. John D, Jeffrey L, David E, Richard W, Scott Berry, Lee A, David S, David L. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med.2013;368: 1092-1100.
23. Bernhard Meier, Bindu Kalesan, Heinrich P, Ahmed A, David Hildick-Smith, Dariusz Dudek, Grethe Andersen, Reda Ibrahim, Gerhard Schuler, Antony S, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med.2013; 368:1083-91.
24. Stortecky S, da Costa BR, Mattle HP, Carroll J, Hornung M, Sievert H, Trelle S, Windecker S, Meier B, Jüni P. Percutaneous closure of Patent foramen oval in patients with cryptogenic embolism: a network meta-analysis. Eur Heart J.2015;36: 120-8.
25. Varotto L, Bregolin G, Paccanaro M, De Boni A, Bonanno C, Perini F. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta- Analysis to Identify the Best Device. Cerebrovasc Dis. 2020;14:1-11.
26. Zhihui Zhang, Qing Yao, Haiyun Huang, Chen Wan, Zhiyuan Song, Huakang Li. Efficacy and safety of dabigatran and dual antiplatelet therapy after left atrial appendage occlusion with the Watchman device. International Journal of Clinical and Experimental Medicine.2018; 11(9): 9819-26.
27. Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Abbey S, Fatemi M, Franceschi F, Guedeney P, Jacon P. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol.2018;71(14):1528 -36.